All In Biotech

Drug Trial Radar · NCT03534453

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

An Open Label, Single Arm, Multicentre Study to Assess the Clinical Efficacy and Safety of Lynparza (Olaparib) Tablets Maintenance Monotherapy in Platinum Sensitive Relapsed Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (L-MOCA)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

May 29, 2018

Primary completion

Jan 27, 2025

Study completion Jan 27, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, single arm, multi-centre interventional study to assess the clinical efficacy and safety of olaparib maintenance monotherapy and will be conducted in patients with platinum sensitive relapsed (PSR) high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy

Conditions

  • Relapsed Ovarian Cancer
  • Following Complete or Partial Response to Platinum Based Chemotherapy
  • Platinum Sensitive

Interventions

  • Olaparib 300mg tabletsDrug

    300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Time from first dose of olaparib until the date of investigator assessed disease progressionaccording to RECIST 1.1 criteria or death, whichever came first,up to 79 months

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Chongqing, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Harbin, China

  • Research Site

    Hefei, China

  • Research Site

    Jinan, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenyang, China

  • Research Site

    Tianjin, China

  • Research Site

    Tianjin, China

  • Research Site

    Wuhan, China

  • Research Site

    Wuhan, China

  • Research Site

    Xi'an, China

  • Research Site

    Zhengzhou, China

  • Research Site

    Ampang, Malaysia

  • Research Site

    Johor Bahru, Malaysia

  • Research Site

    Kuala Lumpur, Malaysia

  • Research Site

    Kuching, Malaysia

  • Research Site

    Putrajaya, Malaysia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.